Hepatitis E Vaccine Provides Long-term Protection

Hepatitis E virus (HEV) is a common cause of acute hepatitis, yet its prevention often receives less attention compared to other hepatitis viruses. Understanding the long-term effectiveness of hepatitis E vaccines is crucial for disease control and prevention efforts.

A recent study conducted in Dongtai County, China, extended a phase-3 clinical trial to evaluate the durability of protection provided by a hepatitis E vaccine over a 10-year period. The initial trial enrolled over 112,000 healthy adults and randomly assigned them to receive either the hepatitis E vaccine or a placebo. This study was published in the journal The Lancet by Shoujie H. and colleagues.

Participants received three doses of the vaccine or placebo intramuscularly at months 0, 1, and 6. A comprehensive surveillance system was established to monitor hepatitis E cases in the study region over the following 10 years. The primary outcome was the efficacy of the vaccine in preventing confirmed cases of hepatitis E occurring at least 30 days after the third dose.

The key findings of the study were:

  • Over the 10-year study period, 90 cases of hepatitis E were identified, with significantly fewer cases in the vaccine group compared to the placebo group.

  • The vaccine demonstrated an efficacy of 83.1% in the modified intention-to-treat analysis and 86.6% in the per-protocol analysis.

  • Moreover, antibody persistence was assessed in subsets of participants, showing that a significant proportion maintained detectable antibody levels even after several years.

The study findings indicate that immunization with the hepatitis E vaccine provides long-lasting protection against hepatitis E, with vaccine-induced antibodies persisting for at least 8.5 years. This underscores the importance of vaccination programs in preventing hepatitis E infections and highlights the effectiveness of the vaccine in reducing disease burden over the long term.

Reference:

Huang, S., Zhang, X., Su, Y., Zhuang, C., Tang, Z., Huang, X., Chen, Q., Zhu, K., Hu, X., Ying, D., Liu, X., Jiang, H., Zang, X., Wang, Z., Yang, C., Liu, D., Wang, Y., Tang, Q., Shen, W., … Xia, N. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet,2024. https://doi.org/10.1016/s0140-6736(23)02234-1

Powered by WPeMatico

Feeling depressed after menopause? Hormone therapy may help

Hormone therapy (HT) is already recognized as the most effective treatment option for physiologic menopause symptoms such as hot flashes, but a new study is one of the first to suggest that it might also help manage depressive symptoms. It further documented a high rate of depression during menopause.

Results of the study have been published online in Menopause, the journal of The Menopause Society.

Depression and other mood-related symptoms can strike at any time during a woman’s life but have been shown to be especially likely during and immediately after the menopause transition. In a new study involving 170 women who were patients at a menopause clinic in Ontario, Canada, there was a high prevalenc-62%-of participants who scored as being “depressed.” Although these symptoms may not necessarily reach the severity of a major depressive disorder, they still could significantly affect quality of life and relationships.

To date, the effectiveness of HT to effectively manage hot flashes (technically known as vasomotor symptoms) has been well documented. However, its ability to address mood-related symptoms is less established. This new study from Canada sought to correct that problem.

Hormone influences on neurotransmitter-receptor pathways, which regulate mood during and after the menopause transition, are thought to play a role in depressive symptoms. In addition, the domino theory suggests that the toll of physiologic symptoms experienced during menopause, such as hot flashes and an array of genitourinary problems, could also contribute to adverse moods.

As part of their study, researchers attempted to determine whether the stage of menopause contributed to an increased risk of depression, but no association was found, although a lower education level (high school or less) and younger age did show a direct correlation. The addition of progestin to the HT regimen did not have a significant effect on overall effectiveness. Additionally, although women who went through natural menopause experienced significant improvements with regard to their depressive symptoms, women who experienced iatrogenic menopause (surgical or chemotherapy based) did not have similar improvements.

On the basis of these results, the researchers concluded that HT-whether used alone or in conjunction with antidepressants-can improve not only hot flashes but also depressive symptoms commonly associated with menopause.

Survey results are published in the article “Does menopause hormone therapy improve symptoms of depression? Findings from a specialized menopause clinic.”

“This study showed a beneficial effect of hormone therapy on mood symptoms during menopause when used alone and a synergistic effect when used in combination with antidepressants. It also highlights the high prevalence of mood symptoms during this transition and the need to address women’s symptoms holistically rather than having a singular focus on hot flash management,” says Dr. Stephanie Faubion, medical director for The Menopause Society.

Reference:

Gnanasegar R, Wolfman W, Galan LH, Cullimore A, Shea AK. Does menopause hormone therapy improve symptoms of depression? Findings from a specialized menopause clinic. Menopause. 2024 Feb 20. doi: 10.1097/GME.0000000000002325.  

Powered by WPeMatico

Vision impairment in older adults tied to symptoms of depression, anxiety and social isolation: JAMA

USA: A cross-sectional study comprising 2822 US adults revealed that worse examination-based and self-reported vision impairment is associated with anxiety and depressive symptoms, and worse examination-based vision impairment is linked with severe social isolation.

These findings, published in JAMA Ophthalmology, provide evidence to support prioritizing research aimed at enhancing the health and inclusion of people with vision impairment.

Vision impairment and psychosocial function, including symptoms of anxiety, depression and social isolation, are a major cause of morbidity in the US. However, there is a lack of nationally representative studies evaluating associations between subjective and objective vision impairment with psychosocial function following the COVID-19 pandemic.

To address this knowledge gap, Louay Almidani, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, and colleagues provided updated national estimates on the associations of vision impairment with depressive and anxiety symptoms and social isolation in US adults 65 years and older.

The study was a cross-sectional analysis of the National Health and Aging Trends Study rounds 9 (2019) and 11 (2021), a nationally representative sample of Medicare beneficiaries aged 65 years and above. Binocular distance visual acuity, contrast sensitivity, and near visual acuity were tested.

Objectively measured vision impairment was defined as vision impairment in either distance visual acuity (worse than 20/40), near visual acuity (worse than 20/40), or contrast sensitivity (worse than 1.55 logCS). Self-reported vision impairment was defined based on participants’ reports on their vision status.

Depression and anxiety symptoms were assessed via the Patient Health Questionnaire. Social isolation was defined based on communication frequency, living arrangement, and activity participation responses.

The researchers reported the following findings:

  • Among 2822 community-dwelling adults sampled from a population of 26 182 090, the mean age was 78.5 years; 54.7% were female; 32.3% had objectively measured vision impairment, and 6.4% had self-reported vision impairment.
  • In adjusted models, all outcomes were significantly associated with objectively measured vision impairment, including depressive symptoms (odds ratio [OR], 1.81), anxiety symptoms (OR, 1.74), and severe social isolation (OR, 2.01).
  • Depressive symptoms (OR, 2.37) and anxiety symptoms (OR, 2.10) but not severe social isolation symptoms (OR, 2.07) were significantly associated with self-reported vision impairment.

In the study, vision impairment was associated with several psychosocial outcomes, including symptoms of depression, anxiety and social isolation.

Reference:

Almidani L, Miller R, Varadaraj V, Mihailovic A, Swenor BK, Ramulu PY. Vision Impairment and Psychosocial Function in US Adults. JAMA Ophthalmol. Published online February 22, 2024. doi:10.1001/jamaophthalmol.2023.6943

Powered by WPeMatico

Study Unveils Complexities of BP Management with Bruton’s Tyrosine Kinase Inhibitors in Lymphoid Malignancies

In a groundbreaking study, researchers
have delved into the optimal approaches for managing hypertension (HTN) in
patients undergoing Bruton’s tyrosine kinase inhibitor (BTKi) treatment, a
revolutionary therapy for lymphoid malignancies. They found that managing HTN in patients undergoing BTKi
treatment can be complex and may necessitate multiple anti-hypertensive
medications.


The
study results were published in the journal Blood Advances.  


While BTKis, such as ibrutinib, have
proven to be generally well-tolerated and less toxic than traditional
chemotherapy options, this research sheds light on the potential challenge of
new or worsening HTN associated with their use.

While Bruton’s tyrosine kinase
inhibitors (BTKis) are typically well-tolerated and exhibit lower toxicity
compared to chemotherapy options for lymphoid malignancies, notable concern
arises as BTKis, including ibrutinib, may trigger the onset or exacerbation of
hypertension (HTN).

The optimal management of HTN associated with BTKis remains
a relatively unexplored territory.

The study, which included 196 patients
with lymphoid malignancies on BTKis and concurrent anti-hypertensive
medications, aimed to identify effective strategies for blood pressure
management. Patients were categorized into two groups based on their HTN status:
those with pre-existing hypertension before starting BTKi treatment (prior-HTN)
and those who developed HTN after initiating BTKi therapy (de novo HTN).

The
analysis considered patients with a minimum of 3 months of follow-up data.

Using generalized estimating
equations, the researchers explored the associations between time-varying mean
arterial pressures (MAPs) and different anti-hypertensive drug categories.

Findings:

  • Among the significant findings, 118 patients had prior-HTN, while 78 developed
    de novo HTN.
  • Notably, patients with prior HTN
    experienced a statistically significant mean MAP reduction when taking a
    combination of beta blockers (BBs) with hydrochlorothiazide (HCTZ), showing a
    reduction of -5.05 mmHg (95% CI -10.0 to -0.0596; p = 0.047).

  • Similarly, patients with de novo HTN
    exhibited a significant MAP reduction when prescribed either an
    angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor
    blocker (ARB) with HCTZ, demonstrating a reduction of -5.47 mmHg (95% CI -10.9 to
    -0.001; p = 0.05).

  • These regimens were also associated
    with the highest percentages of normotensive MAPs.


  • The study’s findings suggest that
    managing HTN in patients undergoing BTKi treatment is intricate and may require
    a multifaceted approach involving multiple anti-hypertensive medications.
  • For
    patients with prior-HTN, combination regimens with BBs and HCTZ appeared to be
    beneficial, while those with de novo HTN showed improved outcomes with
    ACEi/ARBs combined with HCTZ.

The researchers underscore the importance of
further prospective studies to validate these encouraging results.

This breakthrough study not only
enhances our understanding of blood pressure management in the context of
cutting-edge lymphoid malignancy treatments but also underscores the critical
need for personalized approaches to ensure the well-being of patients
navigating these innovative therapeutic landscapes. 

Further reading: Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Doi: https://doi.org/10.1182/bloodadvances.2023011569

Powered by WPeMatico

Silver diamine fluoride additional tool for addressing dentine hypersensitivity and improving QoL of patients, states study

Silver diamine fluoride additional tool for addressing dentine hypersensitivity and improving QoL of patients states a study published in the Journal of Dentistry.

A study was done to assess the clinical evidence for silver diamine fluoride (SDF) to reduce dentine hypersensitivity in adults. Two independent researchers searched the English literature in five databases (Scopus, PubMed, Web of Science, EMBASE and the Cochrane Library) up to 15th July 2023 for clinical trials investigating the desensitising effect of professionally applied SDF to manage dentine hypersensitivity in adults aged 18 or above at any follow-up period. The primary outcome was the change in dentine hypersensitivity between baseline and follow-up visits after SDF application regarding any validated pain outcome measures. The Cochrane guidelines were used for the risk of bias assessment.

Results: Three hundred and thirty-one studies were identified, and four of them were finally included. Three of the included studies were rated as having a ‘low risk’ of bias. The SDF solution reduced dentine hypersensitivity in adults. The percentage reduction in dentine hypersensitivity ranged from 23 % to 56 % after a single application of SDF solution. Moreover, the SDF solution was more effective than potassium nitrate, potassium oxalate and glutaraldehyde plus hydroxyethyl methacrylate in reducing dentine hypersensitivity. Meta-analysis indicated a more significant reduction in visual analogue scales (1–10) by 1.35 (95 % CI:0.9–1.8; p<0.00001) after receiving the SDF application than controls. The included clinical trials showed that SDF solution reduced dentine hypersensitivity in adults. However, clinical trials are few, and their protocol varied from one another. Further well-designed clinical trials should be conducted to provide more evidence on its use to manage dentine hypersensitivity. SDF is cleared as desensitizing agents by the US Food and Drug Administration to manage dentine hypersensitivity, which induces pain, limits food choice, and impacts the quality of life. Evidence from this systematic review informs clinicians and provides researchers insight for future research on SDF use for dentine hypersensitivity.

Reference:

Alice Kit Ying Chan, Yiu Cheung Tsang, Ollie Yiru Yu, Edward Chin Man Lo, Katherine Chiu Man Leung, Chun Hung Chu. Clinical evidence for silver diamine fluoride to reduce dentine hypersensitivity: A systematic review. Journal of Dentistry, Volume 142, 2024, 104868. ISSN 0300-5712, https://doi.org/10.1016/j.jdent.2024.104868. (https://www.sciencedirect.com/science/article/pii/S0300571224000381)

Keywords:

Silver diamine fluoride, additional tool, dentine hypersensitivity, QoL of patients, Journal of Dentistry, Silver diamine fluoride; Dentine hypersensitivity; Oral health; Caries; Older adult, Alice Kit Ying Chan, Yiu Cheung Tsang, Ollie Yiru Yu, Edward Chin Man Lo, Katherine Chiu Man Leung, Chun Hung Chu

Powered by WPeMatico

Increased retinal detachment risk observed among vitiligo patients: Study

Vitiligo is a condition characterized by the loss of skin pigment and has long been known to be associated majorly with various ocular abnormalities. A recent study from Taiwan explored a concerning association between vitiligo and retinal detachment (RD). The key findings of this studywere published in the journal of Clinical and Experimental Dermatology.

The study was conducted as a nationwide population-based cohort study in Taiwan that analyzed data from the Taiwan National Health Insurance Database from 2007 to 2018. This study identified a cohort of 21,132 vitiligo patients and matched them in a 1:4 ratio with non-vitiligo patients based on age, sex and propensity score of comorbidities.

The findings of the study were;

The vitiligo cohort expressed a significantly higher rate of retinal detachment when compared to the non-vitiligo cohort. After adjusting for various factors, including age, sex and comorbidities, the research found that vitiligo patients underwent a 1.44-fold increased risk of retinal detachment.

Also, the vitiligo patients who required treatments such as phototherapy, systemic corticosteroids or immunosuppressants showed an even greater risk, with a marked 1.57-fold increase in retinal detachment risk.

This study emphasized the importance of these findings which highlights the need for increased vigilance among healthcare professionals regarding the ocular health of vitiligo patients. It’s crucial that clinicians consider the potential risk of retinal detachment in these patients who undergo specific treatments.

With vitiligo affecting approximately 1% of the global population, the clear understanding of its potential systemic associations is critical for comprehensive patient care. Thereby, the comprehensive analysis of study that was over a 10-year follow-up period, further solidifies the observed association between vitiligo and retinal detachment.

Reference:

Chen, C.-L., Wu, C.-Y., Chen, Y.-L., Chen, C.-C., Chang, Y.-T., & Wu, C.-Y. (2024). Association between vitiligo and risk of retinal detachment: A population-based cohort study in Taiwan. In Clinical and Experimental Dermatology. Oxford University Press (OUP). https://doi.org/10.1093/ced/llae035

Powered by WPeMatico

Which Antibiotics Best Prevent Infections for Children With Vesicoureteral Reflux?

Children with vesicoureteral reflux often need to take continuous antibiotics to reduce the risk of urinary tract infections (UTIs). But which antibiotics do the best job at preventing these infections?

Researchers in the Division of Urology at Children’s Hospital Los Angeles recently conducted a study to shed more light on this issue. The results were presented in recently at the Societies for Pediatric Urology Congress in Houston.

“This is a complex question because we know that antibiotic resistance patterns are variable, based on region and many other factors,” says Scott Sparks, MD, a pediatric urologist at CHLA who led the study. “We wanted to see if we could identify any definitive trends about antibiotic effectiveness for our patients here in Los Angeles.”

Key findings

Vesicoureteral reflux is typically a congenital condition in which urine flows backward from the bladder to the ureters or kidneys. Reflux commonly resolves on its own as children grow. But until that happens, some patients may benefit from continuous low-dose antibiotic therapy to prevent UTIs.

The retrospective study examined how often these patients have breakthrough UTIs. The study included 402 children with reflux who were seen at CHLA from 2015 to 2021. All the patients were on continuous antibiotic therapy.

The study found that:

  • Patients taking cephalexin had the highest rates of breakthrough UTIs, at 2.52 per 100 person months.
  • Patients taking sulfamethoxazole/trimethoprim also had relatively high rates of infections, at 1.52 per 100 person months.
  • A large percentage of breakthrough UTIs were resistant to both cephalexin and sulfamethoxazole/trimethoprim.
  • Nitrofurantoin had the lowest rates of breakthrough UTIs.

Guiding discussions with families

Dr. Sparks cautions that these findings are specific to the Los Angeles area. Breakthrough rates are also just one factor in deciding on the best antibiotic for a particular patient.

For example, while nitrofurantoin had the lowest rates of infections, it can be difficult for parents to administer. The medicine does not come in a liquid, and because patients with reflux are typically very young, capsules must be opened up and sprinkled on food.

“I think the biggest take-home message is that, while there’s no perfect choice, it’s important for physicians to be aware of the antibiotic resistance patterns in their own community,” Dr. Sparks says.

“I haven’t significantly changed my prescribing patterns based on these findings,” he adds. “But it has helped me have better discussions with families. I can give them more specific data now about each medicine and what they can expect. Then together, we can make the best choice for each child.”

Powered by WPeMatico

Disruption of multiple complement proteins linked to development of islet autoimmunity and type 1 diabetes: Study

A recent study published in the journal of iScience explored the important role of the complement system in the early stages of Type 1 Diabetes (T1D) which could potentially pave the way for improved detection and prevention strategies. Type 1 diabetes is a chronic condition which affects millions worldwide and is characterized by the autoimmune destruction of insulin-producing pancreatic β cells. 

This recent study conducted by the team of Bobbie-Jo Webb-Robertson highlighted the significance of gene-environment interactions in initiating the autoimmune response that leads to T1D. Also, this study reveals that disruptions in the complement system precede the appearance of islet autoantibodies which indicate autoimmunity in T1D patients.

The complement system is a complex network of proteins involved in immune responses that appears to play a crucial role in the pathogenesis of T1D. The research analyzed samples from children at risk of developing T1D and observed lower levels of complement proteins in those who progressed to clinical T1D when compared to the individuals who did not.

These findings suggest that monitoring complement protein levels could be a valuable biomarker for predicting the onset of T1D and potentially intervening to prevent the progression. Targeting the complement pathway could offer new therapeutic options for managing and potentially slowing down or stopping the development of T1D. The outcomes emphasized the significance of the complement system that represents an understudied but promising target to understand and combating the Type 1 Diabetes.

Reference:

Webb-Robertson, B.-J. M., Nakayasu, E. S., Dong, F., Waugh, K. C., Flores, J. E., Bramer, L. M., Schepmoes, A. A., Gao, Y., Fillmore, T. L., Onengut-Gumuscu, S., Frazer-Abel, A., Rich, S. S., Holers, V. M., Metz, T. O., & Rewers, M. J. (2024). Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes. In iScience (Vol. 27, Issue 2, p. 108769). Elsevier BV. https://doi.org/10.1016/j.isci.2023.108769

Powered by WPeMatico

International Study Finds Thrombectomy Highly Effective Long-Term Treatment for Large Strokes

In a major, international study, named SELECT2, a University Hospitals (UH) research team found that patients with large strokes had a dramatically better recovery after endovascular thrombectomy plus medical management at long-term follow-up, than patients who only received standard medical management.

Endovascular thrombectomy is mechanical recovery of a clot that is blocking blood flow in an artery. Size of a stroke is determined by the range of damaged brain tissue seen through CT or MRI scans. While thrombectomy has proven effective in smaller strokes, patients with large strokes have been considered too high risk for the procedure.

The SELECT2 study was a tremendous, global team effort, spearheaded by UH as the coordinating center. A total of 352 patients, ages 18 to 85, with large ischemic strokes were randomized at 31 hospitals in North America, Europe, Australia and New Zealand. The primary findings of SELECT2 trial were published last year in the New England Journal of Medicine, demonstrating better clinical outcomes in patients receiving thrombectomy at the 90-day follow-up. Those findings, along with other trials, established efficacy and safety of endovascular thrombectomy in patients with large core strokes.

However, long-term outcomes for these patients were not explored before. As these patients have suffered large strokes, it remains plausible that they will take a longer time to achieve optimal stroke outcomes. The SELECT2 research team opted to address this question and analyzed patient outcomes after one year. The study published today in The Lancet to coincide with its presentation at the International Stroke Conference (ISC 2024) in Phoenix.

Patients receiving thrombectomy procedure demonstrated close to three times higher rates of independent living and twice the rates of independent walking. For every six patients treated, one achieved better outcomes as compared to medical management only. For a comparison, balloon angioplasty for heart attack only benefits one in 20-50 patients. Patients also demonstrated better quality of life scores.

Global Principal Investigator and Lead Author of the study, Amrou Sarraj, MD, said, “Throughout our research and clinical trials over the past three years, we’ve established that endovascular thrombectomy for patients with large ischemic stroke is safe and effective. However, until now, long-term outcomes for these patients remained widely unknown.” Dr. Sarraj is also the Stroke Center and System Director, the George M. Humphrey II Chair in Neurology at University Hospitals, and Professor of Neurology at Case Western Reserve University School of Medicine.

The SELECT2 results represent a major advancement in stroke therapy worldwide, and will bring hope for patients and families in a subgroup of patients who previously would have been thought not to benefit. The study proved that a higher quality of life for these patients persists for at least one year following intervention.

“Now that we have been able to follow these patients for a full year, we have confirmed the long-term benefits of thrombectomy in patients with large core strokes,” Dr. Sarraj explained. “With the evidence that improvement continues, exploration of how we can further improve these outcomes, including efforts on supportive care, such as rehabilitation and adjunctive therapies, becomes very important.”

“University Hospitals is thrilled to have served as the coordinating site for the transformative, international SELECT2 study expanding the indications for thrombectomy in large strokes,” said Daniel Simon, MD, President, Academic & External Affairs, Chief Scientific Officer, and Ernie and Patti Novak Distinguished Chair in Health Care Leadership at University Hospitals. “The results of this study will impact thousands of patients worldwide, significantly improving their quality of life. We look forward to implementing this practice changing treatment for stroke in our health system.” Dr. Simon is also Professor of Medicine and Senior Associate Dean for Academic Affairs at Case Western Reserve School of Medicine.

Reference:

Amrou Sarraj, Ameer E. Hassan, Michael G. Abraham, Santiago Ortega-Gutierrez, Scott E. Kasner, M. Shazam Hussain, Michael Chen, Spiros Blackburn, Clark W. Sitton, Leonid Churilov, Sophia Sundararajan, Trial of Endovascular Thrombectomy for Large Ischemic Strokes,New England Journal of Medicine, DOI: 10.1056/NEJMoa2214403.

Powered by WPeMatico

DMER Maharashtra Invites Online Applications for Bond Service allotment to Super-Speciality degree holders Summer-2023 Batch, details

Maharashtra: The Directorate of Medical Education & Research (DMER Maharashtra) has invited Online Applications and online allotment of Government Bond Service to Super-Speciality degree holders of Summer-2023 Batch.

The notice states, “As per the Government Resolution No. WPM 1011/CR 352/ll/Edu-2, dated 4th April 2012 the Central Committees has been constituted. The Process of Central round for allotment of bond services to Super Speciality candidates will be carried out by filling online application form and by online allotment as per following schedule. The concerned should note Department wise & Speciality wise available vacant posts being published on DMER website.”

Schedule for Online Application and Online Allotment

Date

Time

Speciality

22.02.2024 to 26.02.2024

from 11.00 am to upto 5.00 pm

Filling of online application form and
online Choice filling process

27.02.2024

after. 5.00 pm.

Declaration of allotment of bond service to
candidate and issue of recommendation letter from web portal through Login ID

Qualification required for Super Speciality Medical Officer – Superspeciality in specific subject.

Note:

All detail information including the number of available vacant posts, eligibility criteria, tie-breaker for selection, list of documents required to be submitted to the institutes will be published on DMER’s website  on 21.02.2024

All eligible candidates must fill online application form on DMER’s website.

Vacancy position of posts is likely to change anytime.

List of eligible candidates for allotment of bond services is available on DMER’s website with the information.

Instructions to the candidates

A) General Instructions :

1. Candidates will be allotted seats as per subject merit for posts of Assistant Professor, Super Speciality Medical Officer, Senior Resident on post in Superspeciality on the basis of marks obtained in Superspeciality degree examination. All posts will be allotted on merit basis as Open Category.

2. All candidates who are eligible for getting bond service as per list attached must fill online application form.

3. If any candidate doses not fill online application form there by refusing to get allotment of bond service, the said candidate will be deemed to be not interested to comply bond service. Hence for such candidate the process of recovery of bond penalty amount will be initiated.

4. Recommendation /Selection will be displayed on DMER website on 26.02.2024

5. Candidate can download Recommendations letter from DMER website www.dmerbond.org through Login ID

6. Candidates should take print out of recommendation letter and report to concerned allotted institute with requisite documents within 7 days from the date of recommendation letter.

7. Helpline Number – 022 22652193, Time 10.00 am to 05.45 pm. strictly.

B) The candidate must submit attested photo copy of requisite documents at respective institute where they will be allotted post as per the list given below:

a) SSC Passing Certificate / valid passport (as proof of age).

b) Superspeciality mark-sheets

c) Degree Mark sheet / Grade Certificate

d) Attempt certificate of all MBBS, MD/MS examinations from the head of the institution.

e) MBBS degree / Passing certificate.

f) MD/M.S. Degree Passing Certificate.

g) Permanent Registration certificate of Maharashtra Medical Council or other State Medical Councils in India/MCI.

h) Online recommendation letter of allotment of bond service, (will be mailed to the candidates on their registered email id)

C) Rule of TIE-BREAKER:

Selection of candidate for the vacant post shall be as per the procedure of preparation of merit list as given below.

First Level:-The Candidate having Highest Mark in DM/MCH postgraduate examination (Superspeciality) will be preferred, ‘

if tie persists then –

Second Level: – The Candidate having Highest aggregate Mark in final MD / MS will be preferred,

if tie persists then –

Third Level: – The Candidate having Highest Mark in Final MBBS will be preferred,

if tie persists then –

Fourth Level: – The older candidate will be preferred

To view the official Notice, Click here : https://medicaldialogues.in/pdf_upload/super-notification-232930.pdf

Powered by WPeMatico